INCYTE CORP
Customers
0
None disclosed
Suppliers
2
2 active
Top supplier share
32%
of MGNX revenue · FY to 2025-12-31
Top supplier by $
$47.8M
MGNX · FY to 2025-12-31
Latest period
Dec 31, 2025
10-K filed 2026-03-10
Suppliers 2
Companies that disclose INCY as a major customer, as a share of their own revenue. 2 active, 0 lapsed.
| Company | % of their revenue | Est. $ from INCY | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| MGNX MACROGENICS INC |
32% | $47.8M | FY 2025-12-31 | −44.0pp | Active | 10-K 2026-03-09 |
The following table includes those counterparties that represent more than 10% of total revenue earned in the periods indicated:Year Ended December 31,202520242023Sanofi S.A. (Sanofi)33%*10%Incyte Corporation (Incyte)32%76%53%Gilead Sciences, Inc (Gilead)24%**ASD Healthcare and Oncology Supply (ASD)**10%McKesson Plasma & Biologics and McKesson Specialty Care Distribution LLC (McKesson)**12% | ||||||
| PRLD Prelude Therapeutics Inc |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-10 |
The Company assessed the Option Agreement in accordance with ASC 606, Revenue from Contracts with Customer, and concluded that Incyte is a customer in the context of the Option Agreement. | ||||||
Alerts are coming
Get an email when INCY's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.